Array Biopharma Inc.

Icos Corporation

Genentech, Inc.

Loxo Oncology, Inc.

Eli Lilly and Company

Mirati Therapeutics, Inc.

Adam Wade Cook

Andrew T Metcalf

David A Moreno

James F Blake

Li Ren

Tony P Tang

Oren T McNulty

Gabrielle R Kolakowski

Steven Wade Andrews

Yutong Jiang

Julia Haas

Barbara J Brandhuber

Elizabeth A McFaddin

Megan L McKenney

Sean Douglas Aronow

Kevin W Hunt

Laurence Edward Burgess

George A Doherty

John Joseph Gaudino

Ronald Jay Hinklin

Ellen Ruth Laird

Christopher T Clark

Indrani W Gunawardana

Christopher Peter Corrette

Shane M Walls

Mark Joseph Chicarelli

John Peter Fischer

Mark Laurence Boys

Martha E Rodriguez

Jay Bradford Fell

Brad Newhouse

Huifen Chen

Edward A Kesicki

Shelley Allen

Lewis J Gazzard

Jacob Bradley Schwarz

Peter J Mohr

Erik James Hicken

Charles Todd Eary

Weidong Liu

Michael Lyon

Qian Zhao

Mark C Munson

Scott D Cowen

John E Robinson

Christopher Ronald Smith

Matthew Arnold Marx

James Gail Christensen

Frank Stappenbeck

Hua Chee Ooi

Ginelle A Ramann

Todd T Romoff

James Collier

Macedonio J Mejia

Ganghyeok Kim

Patrick Michael Barbour

Stacey Spencer

Robert Kirk Delisle

Mike Welch

Mohamed S A Elsayed

Sylvie Asselin

Christina Elizabeth Wong

Katelyn Chando

Zack Crane

Jane Schmidt

Robert Kirk DeLisle

Bradley Jon Newhouse

Philip B Loudin

Allen A Thomas

Spencer Phillip Pajk

Dean Russell Kahn

Joshua Ryan Dahlke

Brett Joseph Prigaro

Eugene Tarlton

Oren Teague Mcnulty

Katie Keaton Brown

Christopher P Corrette

Mohamed S Elsayed

Guy P A Vigers

Pavel Savechenkov

Kathleen S Keegan

Francine S Farouz

Elizabeth A Mcfaddin

Kimba Lee Fischer

Ryan Coatsworth Holcomb

Scott Douglas Cowen

Frank Diaz

Megan L Mckenney

Steve Do

Kimba L Fisher

Eugene Thorsett

Ryan Holcomb

Alexander Rudolph

Oren T Mcknulty

Guy PA Vigers

Andrew Terrance Metcalf

Tony Pisal Tang

Compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula Ia or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed

Protein tyrosine phosphatase inhibitors

Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X, X, X, X, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.

In some embodiments, provided herein is a process for preparing a compound of Formula I or a pharmaceutically acceptable salt thereof, as disclosed herein.

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile

Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R, R, R, Xand G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

Pyrazolo[3,4-b]pyridine compounds as inhibitors of TAM and MET kinases

Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X, X, X, X, Ring D, E, R, R, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors

Provided herein are compounds of the Formula I: and pharmaceutically acceptable salts, solvates and polymorphs thereof, wherein L, X, R, R, R, R, Rand Rare as defined herein, for the treatment of BRAF-associated diseases and disorders, including BRAF-associated tumors, including malignant and benign BRAF-associated tumors of the CNS and malignant extracranial BRAF-associated tumors.

Compounds for the treatment of BRAF-associated diseases and disorders

Compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer, prodrug or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X, X, X, R, Rand Rare as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor. 

Bicyclic fused pyridine compounds as inhibitors of TAM kinases

Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R, R, R, Xand G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.

Process for the preparation of 6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbontrile

Provided herein are compounds of the general Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which X, R, R, R, Ring A and z have the meanings given in the specification, which are inhibitors of FGFR1, FGFR2, FGFR3 and/or FGFR4 and are useful in the treatment and prevention of diseases which can be treated with an FGFR inhibitor, including diseases or disorders mediated by FGFR1, FGFR2, FGFR3 and/or FGFR4.

2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases

Growing community of inventors

Broomfield, CO, United States of America

Adam Wade Cook